title: In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties.
abstract: 1. SB 206553 (5-methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2 ,3-f]indole) displays a high affinity (pK1 7.9) for the cloned human 5-HT2C receptor expressed in HEK 293 cells and the 5-HT2B receptor (pA2 8.9) as measured in the rat stomach fundus preparation. SB 206553 has low affinity for cloned human 5-HT2A receptors expressed in HEK 293 cells (pK1 5.8) and (pK1 < 6) for a wide variety of other neurotransmitter receptors. 2. SB 206553 appears to be a surmountable antagonist of 5-HT-stimulated phosphoinositide hydrolysis in HEK 293 cells expressing the human 5-HT2C receptor (pKB 9.0). 3. The compound potently (ID50 5.5 mg kg-1, p.o., 0.27 mg kg-1, i.v.) inhibited the hypolocomotor response to m-chlorophenylpiperazine (mCPP), a putative model of 5-HT2C/5-HT2B receptor function in vivo. 4. At similar doses (2-20 mg kg-1, p.o.) SB 206553 increased total interaction scores in a rat social interaction test and increased punished responding in a rat Geller-Seifter conflict test. These effects are consistent with the possession of anxiolytic properties. 5. SB 206553 also increased suppressed responding in a marmoset conflict model of anxiety at somewhat higher doses (15 and 20 mg kg-1, p.o.) but also reduced unsuppressed responding. 6. These results suggest that SB 206553 is a potent mixed 5-HT2C/5-HT2B receptor antagonist with selectivity over the 5-HT2A and all other sites studied and possesses anxiolytic-like properties.
authors.affiliation: Department of Psychiatry, SmithKline Beecham Pharmaceuticals, Essex.
authors.forename: G A
authors.initials: GA
authors.lastname: Kennett
authors.forename: M D
authors.initials: MD
authors.lastname: Wood
authors.forename: F
authors.initials: F
authors.lastname: Bright
authors.forename: J
authors.initials: J
authors.lastname: Cilia
authors.forename: D C
authors.initials: DC
authors.lastname: Piper
authors.forename: T
authors.initials: T
authors.lastname: Gager
authors.forename: D
authors.initials: D
authors.lastname: Thomas
authors.forename: G S
authors.initials: GS
authors.lastname: Baxter
authors.forename: I T
authors.initials: IT
authors.lastname: Forbes
authors.forename: P
authors.initials: P
authors.lastname: Ham
authors.forename: T P
authors.initials: TP
authors.lastname: Blackburn
mesh_terms: D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology*; D002144:Callithrix; D002460:Cell Line; D003220:Conflict, Psychological; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D007211:Indoles / Q000494:pharmacology*; D007668:Kidney / Q000187:drug effects / Q000378:metabolism; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D010716:Phosphatidylinositols / Q000378:metabolism; D010879:Piperazines / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology*; D011869:Radioligand Assay; D051381:Rats; D017207:Rats, Sprague-Dawley; D012702:Serotonin Antagonists / Q000494:pharmacology*; D017366:Serotonin Receptor Agonists / Q000494:pharmacology; D012919:Social Behavior
chemical_list: D014151:Anti-Anxiety Agents; D007211:Indoles; D010716:Phosphatidylinositols; D010879:Piperazines; D011725:Pyridines; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists; C094868:SB 206553; C015068:1-(3-chlorophenyl)piperazine